MONTREAL and CHARLOTTE,
N.C., Nov. 21, 2023 /PRNewswire/ -- Milestone
Pharmaceuticals Inc. (Nasdaq: MIST) today announced
that members of its management team will participate in a
fireside chat at the Piper Sandler 35th Annual
Healthcare Conference on Tuesday, November
28, 2023, at 10:30 a.m. Eastern
Time.
The fireside chat is available to watch both live and replay for
approximately 90 days following the presentation in the News &
Events section of Milestone's website
at www.milestonepharma.com.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a
biopharmaceutical company developing and commercializing innovative
cardiovascular solutions to improve the lives of people living with
complex and life-altering heart conditions. The Company's focus on
understanding unmet patient needs and improving the patient
experience has led us to the development of new treatment
approaches that provide patients with an active role in
self-managing their care. Milestone's lead investigational product
is etripamil, a novel calcium channel blocker nasal spray that is
being studied for patients to self-administer without medical
supervision to treat highly symptomatic episodic attacks associated
with paroxysmal supraventricular tachycardia (PSVT) and atrial
fibrillation with rapid ventricular rate (AFib-RVR).
The company recently submitted a New Drug Application to the
U.S. Food and Drug Administration for etripamil, which will be
marketed under the conditionally approved brand name
CARDAMYSTTM for PSVT, a debilitating heart condition
where patients have unpredictable episodes of extremely rapid heart
rate. If approved, it will be the first innovative treatment
solution for PSVT in 30 years. Milestone is also studying etripamil
in AFib-RVR, an irregular heart rhythm with an abnormally rapid
heart rate. Results from the ReVeRA Phase 2 clinical trial were
presented as a Featured Science Session at the American Heart
Association Scientific Sessions 2023 and simultaneously published
in Circulation: Arrhythmia and Electrophysiology. The data
showed that delivery of etripamil nasal spray significantly and
rapidly reduced ventricular rate in patients with AFib, along with
symptoms of rapid rates, consistent with the drug's pharmacologic
profile. Find out more at www.milestonepharma.com.
Contact
Kim Fox, Vice
President, Communications
kfox@milestonepharma.com
704-803-9295
View original content to download
multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-piper-sandler-35th-annual-healthcare-conference-301994219.html
SOURCE Milestone Pharmaceuticals, Inc.